WO1997000956A1 - Molecules d'adherence reagissant a l'hypoxemie, anticorps specifiques et leurs utilisations - Google Patents
Molecules d'adherence reagissant a l'hypoxemie, anticorps specifiques et leurs utilisations Download PDFInfo
- Publication number
- WO1997000956A1 WO1997000956A1 PCT/US1996/010701 US9610701W WO9700956A1 WO 1997000956 A1 WO1997000956 A1 WO 1997000956A1 US 9610701 W US9610701 W US 9610701W WO 9700956 A1 WO9700956 A1 WO 9700956A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cells
- cell
- human
- cell adhesion
- Prior art date
Links
- 206010021143 Hypoxia Diseases 0.000 title claims description 56
- 230000007954 hypoxia Effects 0.000 title claims description 27
- 238000000034 method Methods 0.000 claims abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 50
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims abstract description 49
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims abstract description 48
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 208000035475 disorder Diseases 0.000 claims abstract description 19
- 239000003446 ligand Substances 0.000 claims abstract description 19
- 230000021164 cell adhesion Effects 0.000 claims abstract description 18
- 230000001394 metastastic effect Effects 0.000 claims abstract description 16
- 206010061289 metastatic neoplasm Diseases 0.000 claims abstract description 16
- 230000009826 neoplastic cell growth Effects 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 156
- 210000002889 endothelial cell Anatomy 0.000 claims description 55
- 102000004169 proteins and genes Human genes 0.000 claims description 46
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 31
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 31
- 239000000126 substance Substances 0.000 claims description 23
- 210000001519 tissue Anatomy 0.000 claims description 23
- 210000000265 leukocyte Anatomy 0.000 claims description 20
- 210000005170 neoplastic cell Anatomy 0.000 claims description 19
- 239000003053 toxin Substances 0.000 claims description 17
- 231100000765 toxin Toxicity 0.000 claims description 17
- 108700012359 toxins Proteins 0.000 claims description 17
- 210000004881 tumor cell Anatomy 0.000 claims description 17
- 210000004408 hybridoma Anatomy 0.000 claims description 16
- 210000000663 muscle cell Anatomy 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 208000028867 ischemia Diseases 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 12
- 229960005486 vaccine Drugs 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 230000027455 binding Effects 0.000 claims description 9
- 206010029260 Neuroblastoma Diseases 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 210000005260 human cell Anatomy 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- -1 nitrosoureas Substances 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 6
- 241001529936 Murinae Species 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 230000009401 metastasis Effects 0.000 claims description 6
- 230000001613 neoplastic effect Effects 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 108010052285 Membrane Proteins Proteins 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 238000001361 intraarterial administration Methods 0.000 claims description 5
- 210000003061 neural cell Anatomy 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 210000003606 umbilical vein Anatomy 0.000 claims description 5
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 4
- 102000018697 Membrane Proteins Human genes 0.000 claims description 4
- 238000003384 imaging method Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 150000004676 glycans Polymers 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 150000002739 metals Chemical class 0.000 claims description 3
- 230000003071 parasitic effect Effects 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 239000008177 pharmaceutical agent Substances 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 231100000699 Bacterial toxin Toxicity 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 2
- 231100000742 Plant toxin Toxicity 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 108010039491 Ricin Proteins 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 241000863480 Vinca Species 0.000 claims description 2
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 231100000659 animal toxin Toxicity 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000002280 anti-androgenic effect Effects 0.000 claims description 2
- 229940046836 anti-estrogen Drugs 0.000 claims description 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 239000000051 antiandrogen Substances 0.000 claims description 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 239000000688 bacterial toxin Substances 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000328 estrogen antagonist Substances 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 239000012678 infectious agent Substances 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000002636 mycotoxin Substances 0.000 claims description 2
- 208000017708 myomatous neoplasm Diseases 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000003123 plant toxin Substances 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 150000003212 purines Chemical class 0.000 claims description 2
- 150000003230 pyrimidines Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 150000004804 polysaccharides Polymers 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 230000001575 pathological effect Effects 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 208000010125 myocardial infarction Diseases 0.000 abstract description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 2
- 230000036783 anaphylactic response Effects 0.000 abstract description 2
- 208000003455 anaphylaxis Diseases 0.000 abstract description 2
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 39
- 230000001146 hypoxic effect Effects 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 13
- 238000001262 western blot Methods 0.000 description 12
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 11
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 239000003636 conditioned culture medium Substances 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 9
- 238000001114 immunoprecipitation Methods 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 108010002352 Interleukin-1 Proteins 0.000 description 8
- 102000000589 Interleukin-1 Human genes 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000003511 endothelial effect Effects 0.000 description 7
- 230000009545 invasion Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 6
- 230000004709 cell invasion Effects 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 239000013553 cell monolayer Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229960002378 oftasceine Drugs 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000009650 gentamicin protection assay Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 3
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000013477 bayesian statistics method Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 108010052258 oxygen-regulated proteins Proteins 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100365877 Caenorhabditis elegans cdl-1 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010022657 Intestinal infarction Diseases 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000010062 adhesion mechanism Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000947 motile cell Anatomy 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000023578 negative regulation of cell adhesion Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000007959 normoxia Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- Antibodies can be generated by injecting purified or semi-purified cell adhesion molecules into mammals and harvesting the resulting antisera, or by creating hybridoma cell lines of mammalian origin, such as murine or human, that express anti-cell adhesion molecule antibodies.
- Adhesion molecules are derived from and can be purified from human cells such as endothelial cells, muscle cells, neural cells, hematopoietic cells and neoplastic cells. In mature forms, they exist as cell surface receptors and may be complexed with lipids, saccharides and polysaccharides (e.g. glycosylation), fatty acids (e.g. acylation), other cell surface molecules (factors and co-factors) and additional proteins. Antibodies that bind to these cell surface ligands can prevent their association with other cells and cell surface molecules and, thus, prevent or at least substantially reduce adhesion.
- Reduction of hypoxia- or ischemia-induced adhesion can ameliorate the symptoms associated with oxygen depravation (ischemia) and prevent the tissue damage sometimes associated with, for example, coronary thrombosis, cerebral vascular disease, arteriosclerosis, fibrosis, angiogenesis and tumor formation, plaque formation in arteries or veins, and inflammation as may occur in response to infections of viral, bacterial or parasitic origin.
- ischemia oxygen depravation
- Antibodies to inhibit cell adhesion are also useful to prevent pathological consequences associated with anaphylaxis and other allergic responses compounded by adhesion of cells to damaged tissues. Antibodies may also be useful to treat or prevent the pathological consequences associated with inflammation and the inflammatory process. Many of the steps involve adhesion to cells or other substances. Interference with adhesion can ameliorate or prevent some of the pathological effects associated with inflammation. Antibodies can be administered parenterally or non-parenterally provided they can pass through the gut wall barrier. Preferably methods of parenteral administration include intravenous, subcutaneous, intramuscular or intra-arterial injection of an effective amount.
- Monoclonal antibody HAL 1/13 a murine immunoglobulin (IgC 2a ) was generated by immunizing BALB/c mice with 5 x IO 7 RD cells injected intraperitoneally at least once in one ml serum-free medium.
- IL per ml.
- the cells were washed 5 times with PBS and incubated for 10 minutes at 4°C with a solution containing 2 mM cysteine/5 mM cold Nal, washed one more time and then lysed with ice-cold lysis buffer (1 % triton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne de nouvelles molécules d'adhérence cellulaire et leurs ligands, des gènes codant les molécules d'adhérence cellulaire ou les ligands, ainsi que des anticorps se fixant spécifiquement à ces molécules. On peut utiliser des anticorps afin d'inhiber le processus de l'adhérence cellulaire et de traiter des maladies associées à l'adhérence, telles que l'athérosclérose, l'infarctus du myocarde et la néoplasie métastatique. Ces anticorps peuvent être monoclonaux ou polyclonaux et peuvent être dirigés vers un déterminant antigénique, ou vers un groupe de déterminants antigéniques, de la molécule d'adhérence cellulaire. L'invention concerne également des procédés de traitement ou de prévention de maladies associées à l'adhérence cellulaire, telles que des attaques, l'infarctus du myocarde et les conséquences pathologiques associées à l'anaphylaxie et à l'inflammation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU63906/96A AU6390696A (en) | 1995-06-20 | 1996-06-20 | Hypoxia-responsive adhesion molecules, specific antibodies, nd their uses |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49305395A | 1995-06-20 | 1995-06-20 | |
| US08/493,053 | 1995-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997000956A1 true WO1997000956A1 (fr) | 1997-01-09 |
Family
ID=23958712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/010701 WO1997000956A1 (fr) | 1995-06-20 | 1996-06-20 | Molecules d'adherence reagissant a l'hypoxemie, anticorps specifiques et leurs utilisations |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU6390696A (fr) |
| WO (1) | WO1997000956A1 (fr) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0887076A3 (fr) * | 1997-05-07 | 1999-03-31 | Saturnus A.G. | Prévention d'ahérences et un systeme d'insufflation endoscopique |
| WO1999048916A3 (fr) * | 1998-03-27 | 2000-01-20 | Univ Leland Stanford Junior | Genes et proteines d'origine humaine exprimes dans des conditions d'hypoxie, et utilisations de ceux-ci |
| WO2001023426A3 (fr) * | 1999-09-30 | 2001-11-01 | Varian Associates | Genes humains et proteines relatifs a l'hypoxie et leurs utilisations |
| US8008312B2 (en) | 2005-01-07 | 2011-08-30 | Emory University | CXCR4 antagonists for the treatment of HIV infection |
| US8080659B2 (en) | 2006-07-11 | 2011-12-20 | Emory University | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| US8338448B2 (en) | 2008-03-28 | 2012-12-25 | Altiris Therapeutics, Inc. | Chemokine receptor modulators |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990003400A1 (fr) * | 1988-09-28 | 1990-04-05 | Dana-Farber Cancer Institute | Molecules d'adhesion intercellulaire et leurs ligands de liaison |
| WO1991016928A1 (fr) * | 1990-04-27 | 1991-11-14 | Celltech Limited | ANTICORPS ANTI-MOLECULE 1 d'ADHERENCE INTERCELLULAIRE CHIMERIQUE ADAPTES AU MODELE HUMAIN, PROCEDE DE PREPARATION ET D'UTILISATION |
| WO1993019784A1 (fr) * | 1992-04-07 | 1993-10-14 | The Board Of Trustees Of The Leland Stanford Junior University | Nouvelle molecule d'adherence endotheliale pour monocytes |
| WO1994025067A1 (fr) * | 1993-05-04 | 1994-11-10 | Cytel Corporation | Anticorps diriges contre la selectine p et leurs utilisations |
-
1996
- 1996-06-20 WO PCT/US1996/010701 patent/WO1997000956A1/fr active Application Filing
- 1996-06-20 AU AU63906/96A patent/AU6390696A/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990003400A1 (fr) * | 1988-09-28 | 1990-04-05 | Dana-Farber Cancer Institute | Molecules d'adhesion intercellulaire et leurs ligands de liaison |
| WO1991016928A1 (fr) * | 1990-04-27 | 1991-11-14 | Celltech Limited | ANTICORPS ANTI-MOLECULE 1 d'ADHERENCE INTERCELLULAIRE CHIMERIQUE ADAPTES AU MODELE HUMAIN, PROCEDE DE PREPARATION ET D'UTILISATION |
| WO1993019784A1 (fr) * | 1992-04-07 | 1993-10-14 | The Board Of Trustees Of The Leland Stanford Junior University | Nouvelle molecule d'adherence endotheliale pour monocytes |
| WO1994025067A1 (fr) * | 1993-05-04 | 1994-11-10 | Cytel Corporation | Anticorps diriges contre la selectine p et leurs utilisations |
Non-Patent Citations (8)
| Title |
|---|
| G. HOWARD ET AL.: "Altered cardiac tissue gene expression during acute hypoxic exposure.", MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 69, no. 2, February 1986 (1986-02-01), BOSTON, MA, USA, pages 155 - 160, XP000608995 * |
| I. GINIS ET AL.: "Characterization of a hypoxia-responsive adhesion molecule for leukocytes on human endothelial cells.", THE JOURNAL OF IMMUNOLOGY, vol. 155, no. 2, 15 July 1995 (1995-07-15), BALTIMORE, MD, USA, pages 802 - 810, XP002018002 * |
| I. GINIS ET AL.: "Hypoxia induces lymphocyte adhesion to human mesenchymal cells via an LFA-1-dependent mechanism.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 264, no. 3 part 1, March 1993 (1993-03-01), BETHESDA, MD, USA, pages C617 - C624, XP000608994 * |
| M. ALESSIO ET AL.: "Analysis of the human CD36 leucocyte differentiation antigen by means of the monoclonal antibody NL07.", CELLULAR IMMUNOLOGY, vol. 137, no. 2, 15 October 1991 (1991-10-15), NEW YORK, NY, USA, pages 487 - 500, XP000608990 * |
| M. DE LA TORRE ET AL.: "Expression of the 85-kd membrane protein in primary human breast cancer.", HUMAN PATHOLOGY, vol. 26, no. 2, February 1995 (1995-02-01), PHILADELPHIA, PA, USA, pages 180 - 185, XP000608991 * |
| P. BELITSOS ET AL.: "Homotypic cell aggregation induced by anti-CD44 (pgp-1) monoclonal antibodies and related to CD44 (pgp-1) expression.", THE JOURNAL OF IMMUNOLOGY, vol. 144, no. 5, 1 March 1990 (1990-03-01), BALTIMORE, MD, USA, pages 1661 - 1670, XP002018000 * |
| S. SEITER ET AL.: "Prevention of tumor metastasis formation by anti-variant CD44.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 177, February 1993 (1993-02-01), NEW YORK, NY, USA, pages 443 - 455, XP002018001 * |
| Y. SUGIMOTO ET AL.: "Molecular cloning and characterization of the complementary DNA for the Mr 85,000 protein overexpressed in adriamycin-resistant human tumor cells.", CANCER RESEARCH, vol. 53, no. 11, 1 June 1993 (1993-06-01), BALTIMORE, MD, USA, pages 2538 - 2543, XP002017999 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0887076A3 (fr) * | 1997-05-07 | 1999-03-31 | Saturnus A.G. | Prévention d'ahérences et un systeme d'insufflation endoscopique |
| WO1999048916A3 (fr) * | 1998-03-27 | 2000-01-20 | Univ Leland Stanford Junior | Genes et proteines d'origine humaine exprimes dans des conditions d'hypoxie, et utilisations de ceux-ci |
| WO2001023426A3 (fr) * | 1999-09-30 | 2001-11-01 | Varian Associates | Genes humains et proteines relatifs a l'hypoxie et leurs utilisations |
| US8008312B2 (en) | 2005-01-07 | 2011-08-30 | Emory University | CXCR4 antagonists for the treatment of HIV infection |
| US8114884B2 (en) | 2005-01-07 | 2012-02-14 | Emory University | CXCR4 antagonists for the treatment of medical disorders |
| US8080659B2 (en) | 2006-07-11 | 2011-12-20 | Emory University | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| US8338448B2 (en) | 2008-03-28 | 2012-12-25 | Altiris Therapeutics, Inc. | Chemokine receptor modulators |
| EP2664618A2 (fr) | 2008-03-28 | 2013-11-20 | Altiris Therapeutics | Modulateurs du récepteur de chimiokine |
| US9314468B2 (en) | 2008-03-28 | 2016-04-19 | Altiris Therapeutics, Inc. | Chemokine receptor modulators |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6390696A (en) | 1997-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3541296B2 (ja) | 腫瘍血管内皮細胞に特異的に結合するモノクローナル抗体とその利用方法 | |
| Seon et al. | Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. | |
| US5677171A (en) | Monoclonal antibodies directed to the HER2 receptor | |
| US5725856A (en) | Monoclonal antibodies directed to the HER2 receptor | |
| JP3589459B2 (ja) | 生物応答調節物質の新規な抗体運送システム | |
| JP3600617B2 (ja) | ヒト上皮細胞成長因子レセプターに特異的なモノクローナル抗体及びそれを用いた治療剤 | |
| US5470571A (en) | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 | |
| US20020192211A1 (en) | Method of treating tumor cells by inhibiting growth factor receptor function | |
| US20110020332A1 (en) | Prevention of tumors with monoclonal antibodies against neu | |
| JP2001521520A (ja) | 抗α▲下ｖ▼β▲下３▼インテグリン抗体アンタゴニスト | |
| JPH06506833A (ja) | 幹細胞因子レセプターに対するモノクローナル抗体 | |
| EP0575321A1 (fr) | Therapie anticancereuse synergique combinant des anticorps antitumoraux biologiquement actifs et la chimiotherapie | |
| US6086877A (en) | Therapeutic agent for rheumatic disease | |
| DE69431167T2 (de) | Verfahren zum selektiven methioninentzug für maligne säugetierzellen | |
| WO1997000956A1 (fr) | Molecules d'adherence reagissant a l'hypoxemie, anticorps specifiques et leurs utilisations | |
| KR910002373B1 (ko) | 슈도모나스 에루기노사 편모에 대한 단일클론항체 | |
| US5055559A (en) | Anti-melanoma antibody MG-21 for diagnosis and therapy of human tumors | |
| JPH01126558A (ja) | 抗体依存性細胞性細胞毒性の測定方法 | |
| US6440733B1 (en) | Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel | |
| US5523085A (en) | Monoclonal antibody in destruction of small cell lung carcinoma | |
| US20060177454A1 (en) | Method of promoting an immune response with a bispecific antibody | |
| IE921810A1 (en) | Me20: monoclonal antibodies and antigen for human melanoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |